A study found that co-administration of azithromycin with hydroxychloroquine in rheumatoid arthritis patients increased the risk of cardiovascular events and mortality. Healthcare professionals should consider the benefits and risks of co-prescribing systemic macrolides with hydroxychloroquine. A European safety review reported psychiatric reactions associated with hydroxychloroquine typically occur within the first month of treatment, even in patients without a history of psychiatric disorders.
